{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:22:16Z","timestamp":1791883336517,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.7759\/cureus.44582","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T21:03:26Z","timestamp":1693688606000},"source":"Crossref","is-referenced-by-count":28,"title":["Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics"],"prefix":"10.7759","author":[{"given":"Abdelrahman","family":"Abaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faten","family":"Sid Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humna","family":"Anis Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilma","family":"Vahora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Prasad","family":"Moparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdah T","family":"Al Rushaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana Reddy","family":"Muddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omobolanle  A","family":"Obajeun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo  P","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan B","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018, 131:58-67. 10.1182\/blood-2017-06-741033","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma P","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015, 161:205-14. 10.1016\/j.cell.2015.03.030","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang Y","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019, 15:1111-22. 10.1080\/21645515.2019.1571892","journal-title":"Hum Vaccin Immunother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi M","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022, 21:28. 10.1186\/s12943-021-01489-2","journal-title":"Mol Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen X","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018, 362:k3529. 10.1136\/bmj.k3529","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine J","year":"2015","unstructured":"Sunshine J, Taube JM. PD-1\/PD-L1 inhibitors. Curr Opin Pharmacol. 2015, 23:32-8. 10.1016\/j.coph.2015.05.011","journal-title":"Curr Opin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha JH","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019, 76:359-70. 10.1016\/j.molcel.2019.09.030","journal-title":"Mol Cell"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204853","article-title":"PD-L1","volume":"71","author":"Kythreotou A","year":"2018","unstructured":"Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018, 71:189-94. 10.1136\/jclinpath-2017-204853","journal-title":"J Clin Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren D","year":"2020","unstructured":"Ren D, Hua Y, Yu B, et al.. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020, 19:10.1186\/s12943-020-1144-6","journal-title":"Mol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang Z","year":"2020","unstructured":"Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker. Cancer Med. 2020, 9:8086-121. 10.1002\/cam4.3410","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson K","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol. 2020, 11:568931. 10.3389\/fimmu.2020.568931","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC","volume":"15","author":"Gao S","year":"2020","unstructured":"Gao S, Li N, Gao S, et al.. Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol. 2020, 15:816-26. 10.1016\/j.jtho.2020.01.017","journal-title":"J Thorac Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara K","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, et al.. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022, 603:942-8. 10.1038\/s41586-022-04508-4","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda R","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, et al.. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020, 6:676-84. 10.1001\/jamaoncol.2019.6650","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma P","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015, 348:56-61. 10.1126\/science.aaa8172","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh M","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009, 114:1537-44. 10.1182\/blood-2008-12-195792","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade J","year":"2010","unstructured":"Fourcade J, Sun Z, Benallaoua M, et al.. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010, 207:2175-86. 10.1084\/jem.20100637","journal-title":"J Exp Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed MF","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018, 175:313-26. 10.1016\/j.cell.2018.09.035","journal-title":"Cell"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman GJ","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al.. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000, 192:1027-34. 10.1084\/jem.192.7.1027","journal-title":"J Exp Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi F","year":"2011","unstructured":"Shi F, Shi M, Zeng Z, et al.. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011, 128:887-96. 10.1002\/ijc.25397","journal-title":"Int J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7659462","article-title":"CD80 expressed by CD8(+) T cells contributes to PD-L1-induced apoptosis of activated CD8(+) T cells","author":"Rollins MR","year":"2017","unstructured":"Rollins MR, Gibbons Johnson RM. CD80 expressed by CD8(+) T cells contributes to PD-L1-induced apoptosis of activated CD8(+) T cells. J Immunol Res. 2017, 10.1155\/2017\/7659462","journal-title":"J Immunol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.11.017","article-title":"Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues","volume":"40","author":"Honda T","year":"2014","unstructured":"Honda T, Egen JG, L\u00e4mmermann T, Kastenm\u00fcller W, Torabi-Parizi P, Germain RN. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity. 2014, 40:235-47. 10.1016\/j.immuni.2013.11.017","journal-title":"Immunity"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8\u207a tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros A","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, et al.. PD-1 identifies the patient-specific CD8\u207a tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014, 124:2246-59. 10.1172\/JCI73639","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00550","article-title":"The pd1:pd-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan K","year":"2016","unstructured":"Bardhan K, Anagnostou T, Boussiotis VA. The pd1:pd-L1\/2 pathway from discovery to clinical implementation. Front Immunol. 2016, 7:550. 10.3389\/fimmu.2016.00550","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon KM","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018, 62:29-39. 10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer A","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al.. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017, 389:255-65. 10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0427-6","article-title":"Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?","volume":"6","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, Zhou H, Zhang L. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?. J Immunother Cancer. 2018, 6:135. 10.1186\/s40425-018-0427-6","journal-title":"J Immunother Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920936084","article-title":"Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer","volume":"12","author":"Han HJ","year":"2020","unstructured":"Han HJ, Li YR, Roach M, Aggarwal R. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2020, 12:10.1177\/1758835920936084","journal-title":"Ther Adv Med Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.384","article-title":"PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer","volume":"28","author":"Crane CA","year":"2009","unstructured":"Crane CA, Panner A, Murray JC, et al.. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009, 28:306-12. 10.1038\/onc.2008.384","journal-title":"Oncogene"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2019.4204","article-title":"Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: a new clinical paradigm in the treatment of triple-negative breast cancer","volume":"19","author":"Cyprian FS","year":"2019","unstructured":"Cyprian FS, Akhtar S, Gatalica Z, Vranic S. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: a new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci. 2019, 19:227-33. 10.17305\/bjbms.2019.4204","journal-title":"Bosn J Basic Med Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071033","article-title":"PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging - a literature review","volume":"11","author":"Planes-Laine G","year":"2019","unstructured":"Planes-Laine G, Rochigneux P, Bertucci F, Chr\u00e9tien AS, Viens P, Sabatier R, Gon\u00e7alves A. PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging - a literature review. Cancers (Basel). 2019, 11:1033. 10.3390\/cancers11071033","journal-title":"Cancers (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim ST","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, et al.. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018, 24:1449-58. 10.1038\/s41591-018-0101-z","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0129","article-title":"Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"24","author":"Morse MA","year":"2019","unstructured":"Morse MA, Overman MJ, Hartman L, et al.. Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer. Oncologist. 2019, 24:1453-61. 10.1634\/theoncologist.2019-0129","journal-title":"Oncologist"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.04.003","article-title":"Immunotherapy of colorectal cancer: challenges for therapeutic efficacy","volume":"76","author":"Ciardiello D","year":"2019","unstructured":"Ciardiello D, Vitiello PP, Cardone C, Martini G, Troiani T, Martinelli E, Ciardiello F. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019, 76:22-32. 10.1016\/j.ctrv.2019.04.003","journal-title":"Cancer Treat Rev"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry AB","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al.. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017, 389:2492-502. 10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0777-4","article-title":"Immune checkpoint therapy in liver cancer","volume":"37","author":"Xu F","year":"2018","unstructured":"Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018, 37:110. 10.1186\/s13046-018-0777-4","journal-title":"J Exp Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01120-z","article-title":"Immunotherapy for non-melanoma skin cancer","volume":"23","author":"Shalhout SZ","year":"2021","unstructured":"Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. Immunotherapy for non-melanoma skin cancer. Curr Oncol Rep. 2021, 23:125. 10.1007\/s11912-021-01120-z","journal-title":"Curr Oncol Rep"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver N","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, et al.. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019, 9:370-83. 10.1158\/2159-8290.CD-18-0774","journal-title":"Cancer Discov"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang Q","year":"2022","unstructured":"Tang Q, Chen Y, Li X, et al.. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022, 13:10.3389\/fimmu.2022.964442","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/179669-programmed-cell-death-protein-1-pd-1-and-programmed-cell-death-ligand-1-pd-l1-immunotherapy-a-promising-breakthrough-in-cancer-therapeutics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:45Z","timestamp":1707508425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/179669-programmed-cell-death-protein-1-pd-1-and-programmed-cell-death-ligand-1-pd-l1-immunotherapy-a-promising-breakthrough-in-cancer-therapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.44582","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,2]]}}}